Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Marcus Schindler net worth and biography

Marcus Schindler Biography and Net Worth

EVP of Novo Nordisk A/S

Dr Schindler joined Novo Nordisk in January 2018 as Senior Vice President for External Innovation and Strategy.
From March 2018 to 2021 he was Senior Vice President for Global Drug Discovery and in March 2021 Dr Schindler was appointed Executive Vice President Research & Early Development and Chief Scientific Officer.

Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germany after having started his career with Glaxo Wellcome/GSK, UK in 1997. Dr Schindler holds a PhD from the University of Cambridge, UK.

Dr Schindler is an Adjunct Professor of Pharmacology at the University of Gothenburg, Sweden.

How old is Marcus Schindler?: Dr. Schindler is currently 58 years old. There are 7 older executives and no younger executives at Novo Nordisk A/S. Learn More on Marcus Schindler's age.
How do I contact Marcus Schindler?: The corporate mailing address for Dr. Schindler and other Novo Nordisk A/S executives is Novo Alle, Bagsvaerd G7, 2880. Novo Nordisk A/S can also be reached via phone at (454) 444-8888 and via email at [email protected]. Learn More on Marcus Schindler's contact information.
Has Marcus Schindler been buying or selling shares of Novo Nordisk A/S?: Marcus Schindler has not been actively trading shares of Novo Nordisk A/S during the last ninety days. Learn More on Marcus Schindler's trading history.
Who are Novo Nordisk A/S's active insiders?: Novo Nordisk A/S's insider roster includes Lars Jørgensen (President), Karsten Knudsen (Exec. VP), and Marcus Schindler (EVP). Learn More on Novo Nordisk A/S's active insiders.

Marcus Schindler Insider Trading History at Novo Nordisk A/S

Marcus Schindler Buying and Selling Activity at Novo Nordisk A/S

Novo Nordisk A/S Company Overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Today's Range

Now: $122.70

$122.46

$124.54

50 Day Range

MA: $126.36

$119.74

$135.87

2 Week Range

Now: $122.70

$75.56

$138.28

Volume

5,181,119 shs

Average Volume

4,882,816 shs

Market Capitalization

$550.62 billion

P/E Ratio

45.36

Dividend Yield

1.07%

Beta

0.41